Published in

BMJ Publishing Group, BMJ Open, 10(12), p. e065440, 2022

DOI: 10.1136/bmjopen-2022-065440

Links

Tools

Export citation

Search in Google Scholar

<sup>18</sup>F-FDG-PET hypometabolism as a predictor of favourable outcome in epilepsy surgery: protocol for a systematic review and meta-analysis

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

IntroductionA substantial proportion of patients who undergo surgery for drug resistant focal epilepsy do not become seizure free. While some factors, such as the detection of hippocampal sclerosis or a resectable lesion on MRI and electroencephalogram-MRI concordance, can predict favourable outcomes in epilepsy surgery, the prognostic value of the detection of focal hypometabolism with18F-fluorodeoxyglucose positive emission tomography (18F-FDG-PET) hypometabolism is uncertain. We propose a protocol for a systematic review and meta-analysis to examine whether localisation with18F-FDG-PET hypometabolism predicts favourable outcomes in epilepsy surgery.Methods and analysisA systematic literature search of Medline, Embase and Web of Science will be undertaken. Publications which include evaluation with18F-FDG-PET prior to surgery for drug resistant focal epilepsy, and which report ≥12 months of postoperative surgical outcome data will be included. Non-human, non-English language publications, publications with fewer than 10 participants and unpublished data will be excluded. Screening and full-text review of publications for inclusion will be undertaken by two independent investigators, with discrepancies resolved by consensus or a third investigator. Data will be extracted and pooled using random effects meta-analysis, with heterogeneity quantified using the I2analysis.Ethics and disseminationEthics approval is not required. Once complete, the systematic review will be published in a peer-reviewed journal.PROSPERO registration numberCRD42022324823.